RxDoctor Payments Data

Ross Kommor, MD

Gastroenterology · Marietta, GANPI 1972588051

Payments from drug & device makers

$4,267in general payments, 2019–2025

Across 49 payments — averaging $87.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Janssen Scientific Affairs, LLC$561
  • Pfizer$449
  • Regeneron$280
  • Ardelyx, Inc.$162
  • Covidien LP$135
  • plus $508 from 6 others

What the payments were for

  • Speaking & faculty fees$3007%
  • Food & beverage$3,95293%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,267 in reported general payments places this provider in the 50th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$172,744
Medicare patients
454
Services billed
3,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab21$559,609
RinvoqUpadacitinib12$100,504
Humira(Cf) PenAdalimumab11$74,496
LinzessLinaclotide33$35,715
Mesalamine46$20,985
Dexlansoprazole DrDexlansoprazole26$5,556
SutabSod Sulf/Pot Chloride/Mag Sulf34$5,446
Colestipol Hcl41$3,610
Omeprazole343$3,374
Pantoprazole Sodium146$2,405
Colesevelam Hcl12$2,127
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg60$1,285
Esomeprazole Magnesium44$1,180
Famotidine107$1,168
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$1,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$116$559,60921 claims
AbbVieRinvoq, Linzess$2,172$136,21945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →